T Rose Clinical, Inc.   Report issue

For profit Phase 2
Founded: Raleigh NC United States (2001)

Organization Overview

First Clinical Trial
2018
NCT03395028
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

T Rose Clinical, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

Filgrastim (neupogen) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Biliary Atresia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1